The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > REGULATORY
REGULATORY
- Scope of Japan-EU GMP Mutual Recognition Agreement for Pharmaceuticals Expanded: MHLW
July 19, 2018
- Boehringer’s DPP-4/SGLT2 Combo Up for MHLW Panel Review on July 27
July 17, 2018
- MHLW to Introduce Guidelines for Sales Reps’ Activities, Calling for the Creation of Supervising Offices
July 17, 2018
- New Medical Infrastructure Law to Pave Way for Database on 50 Million People: Govt Official
July 13, 2018
- MHLW Orders Removal of Pregnancy Contraindications for 3 Immunosuppressants
July 12, 2018
- MHLW Selects 9 Priority Prefectures for Generic Promotion Project, but Leaves Tokyo Out
July 12, 2018
- Generic Makers Should Shift to Biologics Biz for Survival: MHLW Official
July 11, 2018
- MHLW Official Expounds on “Authorized Biosimilar” Pricing, 50% Generic Rule Applies for “Biosame” Products
July 11, 2018
- Cabinet OKs FY2019 Budget Guidelines, Allows Request for 600 Billion Yen Social Security Cost Rise
July 11, 2018
- Prices for High-Cost Techs Will Settle Down as They Penetrate Market with Public Health Coverage: MHLW Bureau Chief
July 10, 2018
- Tokyo Govt to Launch Support Program for Drug Discovery Startups to Solve Obstacles to Fundraising, IP Strategy
July 10, 2018
- Reduce Dose, or Discontinue Biologics for Patients with Low RA Disease Activity: Report
July 9, 2018
- Govt Dodges Lawmaker Inquiry on Timing of 2019 Drug Price Revision
July 9, 2018
- LDP Lawmakers to Sort Out Life Science Issues over This Summer
July 6, 2018
- Council OKs Public Knowledge-Based Submissions for New Azathioprine, Temozolomide Indications
July 5, 2018
- Govt Likely to Allow 600 Billion Yen Rise for FY2019 Social Security Budget Request
July 4, 2018
- Several Brand-Name Drug Makers Intend to Withdraw “G1” LLPs
July 4, 2018
- LDP Lawmakers Launch New Study Group on Life Science Industry
July 3, 2018
- MHLW OKs 1st Pfizer Biosimilar, Add’l Indications and Dosages
July 3, 2018
- MHLW Approves Entyvio, Imfinzi, Lynparza Breast Cancer Use, and More
July 3, 2018
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…